1 of 1
Story summary
- Food and Drug Administration (FDA) Commissioner Marty Makary faces scrutiny from Trump officials amid agency turmoil, linked to the pending retirement of Dr. Richard Pazdur.
- Pazdur's departure raises concerns about the FDA's drug review process.
- White House officials express confidence in Makary's leadership despite FDA upheaval.
- Pazdur has warned about political interference in drug reviews and safety standards.
- Some Trump allies downplay Pazdur's exit as typical for a career official.
